Although initial metanalyses on SGLT21/GLP-1 combination reporting greater reductions in HbA1c, SBP, and body weight were not powered or did not assess MACE or all-cause mortality, a later meta-analysis of CVOTs using SGLT2i or GLP-1 reported significant reductions in MACE (30%), cardiovascular mortality/hospitalization due to heart failure (31%), and all-cause mortality (57%) compared with monotherapy with either SGLT2i or GLP-1RA [18, 48]. The gene discussed is GCG; the disease is heart failure.